North America Digital Therapeutics Market Share by Size and Growth 2028

The North America digital therapeutics market is expected to reach US$ 7,323.29 million by 2028 from US$ 1,740.46 million in 2021; it is estimated to grow at a CAGR of 22.8% from 2021 to 2028.

The growth of the market is attributed to the rising prevalence of chronic diseases and growing need to reduce the cost of healthcare. However, cyber threat and risk related to data security restrict the market growth.

Chronic diseases, such as heart disease, stroke, diabetes, and obesity, account for most of the healthcare costs of any country. According to a report by the World Health Organization (WHO), 463 million adults in the world had diabetes in 2020, and the number is expected to rise to 629 million by 2045. Moreover, as per the Centers for Disease Control and Prevention (CDC) data published in 2018, 1.4 million Americans are diagnosed with diabetes every year in the US. According to the IDF Diabetes Atlas 2021, published by the International Diabetes Federation, North America reported ~51 million people affected by diabetes in 2021, and the number is expected to reach 63 million by 2045. As per a report by the American College of Cardiology Foundation, coronary heart disease (CHD) was a leading cause of death in the US in 2018, attributable to cardiovascular disease (CVD), followed by stroke (16.8%), high BP (9.4%), heart failure (9.0%), and other CVDs (17.9%). By 2035, ~130 million adults in the US population are projected to suffer from some form of CVDs.

The obesity rates are increasing rapidly in developed and developing economies in North America due to sedentary and unhealthy lifestyles. As per data published by the Organization for Economic Co-operation (OECD) in 2017, ~19.5% of the adult population was obese in OECD area. This rate is less than 6% in Korea and Japan, and more than 30% in Hungary, New Zealand, Mexico, and the US. Obesity levels are anticipated to reach ~47%, ~39%, and ~35% in the US, Mexico, and England, respectively, by 2030.

To enhance chronic disease management and offer various treatment options to patients, digital therapeutics help deliver evidence-based therapeutic solutions. It enable patients to better control their care and provides potential solutions for chronic diseases management, such as diabetes. Hence, the rise in the prevalence of chronic diseases is driving the digital therapeutics market growth.

North America Digital Therapeutics Market Revenue and Forecast to 2028 (US$ Million)

North America Digital Therapeutics Market Segmentation

By Application

Diabetes
Cardiovascular Diseases
Central Nervous System (CNS) Disease
Respiratory
Smoking Cessation
Musculoskeletal Diseases
Others

By End User

Patients
Providers
Payers
Employers

By Country

US
Canada
Mexico

Company Profiles

Propeller Health (ResMed)
Canary Health
Noom, Inc
2Morrow, Inc.
Teladoc Health, Inc.
Welldoc, Inc.
Fitbit, Inc.
Omada Health, Inc.
MANGO HEALTH
Pear Therapeutics, Inc.

North America Digital Therapeutics Market Strategic Insights

Get more information on this report

North America Digital Therapeutics Market Segmentation Analysis

North America Digital Therapeutics Market Report Highlights

North America Digital Therapeutics Report Scope

Report Attribute	Details
Market size in 2021	US$ 1,740.46 Million
Market Size by 2028	US$ 7,323.29 Million
CAGR (2021 - 2028)	22.8%
Historical Data	2019-2020
Forecast period	2022-2028
Segments Covered	By Application Diabetes Cardiovascular Diseases Central Nervous System Disease Respiratory Diseases Smoking Cessation Musculoskeletal Diseases By Distribution Channel Patients Providers Payers Employers
Regions and Countries Covered
North America	US, Canada, Mexico
Market leaders and key company profiles	Propeller Health (ResMed) Canary Health Noom, Inc 2Morrow, Inc. Teladoc Health, Inc. Welldoc, Inc. Fitbit, Inc. Omada Health, Inc. MANGO HEALTH Pear Therapeutics, Inc.